suvratoxumab

Reeling from AstraZeneca's termination of pneumonia collab, Aridis lays off 20% of staff
Fierce Biotech
Mon, 04/3/23 - 10:14 am
AstraZeneca
Aridis Pharmaceuticals
MedImmune
monoclonal antibodies
suvratoxumab
layoffs